Volume 2 Supplement 2

Abstracts from the 1st Immunotherapy of Cancer Conference (ITOC1)

Open Access

P25. Access to diagnostics: a bottleneck for immunotherapeutics development - case example of MAGE-A3 cancer immunotherapeutic

  • K Lykopoulos1,
  • P Collins2,
  • M Hall2,
  • R Ehness3,
  • J Barth3 and
  • J Louahed2
Journal for ImmunoTherapy of Cancer20142(Suppl 2):P16

https://doi.org/10.1186/2051-1426-2-S2-P16

Published: 12 March 2014

Precision medicine with modern immunotherapeutics often requires pre-therapeutic access to novel and sometimes complex diagnostic tests. Test development and access to tests including reimbursement often lacks behind medicine development and availability of medicines, potentially creating a gap for physicians to administer and patients to receive an optimised treatment regime. Pharmaceutical companies are challenged by the fact of having to co-develop a diagnostic method, a process which many of them are not accustomed to. In addition, many healthcare systems have no way of allowing in parallel evaluation of diagnostic test and medicine with a view to reimbursement.

This presentation illustrates approaches using the developmental history of the MAGE-A3 cancer immunotherapeutic to both address the developmental hurdle through innovative models and partnerships, as well as the market access hurdle through appropriate market understanding and evidence generation.

Insights and solutions of pre-clinical, clinical and market research/insight will be presented.

Authors’ Affiliations

(1)
GSK
(2)
GSK Vaccines
(3)
GSK

Copyright

© Lykopoulos et al; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement